proven to be 76% as effective as tamoxifen in reducing the overall risk of invasive breast cancer (RR, 1.24; 95% CI, 1.05–1.47). 6 Two aromatase inhibitors have been investigated for the primary prevention of breast cancer. MAP.3 was a randomized
Search Results
Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster
Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor, and Courtney Vito
/radiation, or mastectomy. 1 When breast conservation is used, the risk of local recurrence is higher than with mastectomy. 1 Antiestrogen (anti-e) therapy, in the form of either tamoxifen or an aromatase inhibitor (AI), may be used to reduce the risk of local
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
6 months after treatment. Median and mean time taking opioids was 0.7 and 1.9 weeks, respectively. New opioid users were more likely to receive multimodality treatment and aromatase inhibitors, and persistent opioid users were more likely to receive
D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff
2006 ; 11 : 704 – 717 . 42 Miller WR Bartlett J Brodie AM . Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008 ; 13 : 829 – 837 . 43 Normanno
Adam L. Cohen and John H. Ward
with breast cancer stop taking it early. 15 – 17 Therefore, an individualized approach to balancing the benefits and risks of tamoxifen is appropriate. Risk Reduction With Other Drugs Both aromatase inhibitors and human epidermal growth factor
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
postmenopausal women, except that tamoxifen is the preferred adjuvant treatment. 5 – 9 There are limited clinical data on the efficacy of single-agent aromatase inhibitors in men, and aromatase inhibitors may be combined with gonadotropic hormone
Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith
-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Presented at the 2006 San Antonio Breast Cancer Symposium ; December 14–17, 2006 ; San
Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall
premenopausal women with early-stage breast cancer; the NCCN Guidelines recommend tamoxifen alone. The AGO guidelines recommend either tamoxifen or an aromatase inhibitor (AI) for postmenopausal women with early-stage breast cancer; the NCCN Guidelines
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
will receive endocrine therapy (tamoxifen or an aromatase inhibitor [AI]; category 1). Adjuvant RT After Mastectomy Multiple trials have reported decrease in locoregional recurrence and OS benefit in patients receiving postmastectomy RT (PMRT
Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal
testosterone and its derivatives with some clinical efficacy. 2 However, androgen therapy fell out of favor due to concerns of aromatization to its virilizing effects, and the availability of tamoxifen and third-generation aromatase inhibitors (AIs). 3
